BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
» Products Receiving Approvable Letters From FDA
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
Products Receiving Approvable Letters From FDA
Jan. 1, 2000
No Comments
Company
Product
Description
Indication
Action/Date
Chiroscience Group plc (UK)
Chirocaine
Levobupivacaine; chiral version of bupavicaine
Long-acting local anesthetic
Received approvable letter (3/1)
DUSA Pharmaceuticals Inc. (Canada)
Levulan
Photodynamic therapy; 20% solution of amino-levulinic acid HCl (topical)
Multiple actinic keratoses of the face and scalp
Received approvable letter (6/29)
Ergo Science Corp.
Ergoset
Bromocriptine mesylate
Type 2 diabetes
Received approvable letter for NDA (10/21)
Novartis AG (Switzerland)
Exelon
Rivastigmine tartrate capsules
Mild-to-moderate Alzheimer's disease
Received approvable letter (5/13)
Article reprints
BioWorld MedTech